

Supplementary Table 1. Demographic and clinical characteristics of COVID-19 patients responding or not to tocilizumab.

These data are referred to hospital admission, before starting therapy (T0).

Variable	RESPONDERS (n=13)	NON-RESPONDERS (n=10)
Demographic characteristics		
Age (mean years, range)	60.1 (40 – 85)	69.9 (53 – 81)
Sex (M,%)	69.2	80.0
Clinical characteristics		
Respiratory rate	24 (16 – 37)	29.5 (18 – 40)
Heart rate	77.4 (60 – 112)	93.6 (83 – 148)
SOFA score, mean (range)	2.5 (1 – 4)	3.7 (2 – 7)
Coexisting conditions		
Type 2 diabetes, N (%)	0 (0)	2 (20)
Cardiovascular Dis., N (%)	1 (8.3)	1 (10)
Obesity, N (%)	0 (0)	1 (10)
Arterial blood gas analysis		
pO ₂ , mmHg (range)	64.3 (47.2 – 96.5)	59.3 (49.4 – 67.3)
sO ₂ , % (range)	90.7 (62.0 – 97.8)	91.5 (86.6 – 94.6)
pCO ₂ , mmHg (range)	37.0 (31.6 – 43.6)	35.3 (30.0 – 40.1)
pO ₂ /FiO ₂ (range)	231.5 (72.0 – 296.0)	162.1 (52 – 292.0)
Blood parameters		
ALT, U/L (range)	43.7 (15.0 – 75.0)	27.8 (19.0 – 40.0)
Total bilirubin, mg/dL (range)	0.7 (0.4 – 1.1)	0.6 (0.3 – 1.46)
CK, U/L (range)	195.7 (24.0 – 442.0)	210.2 (52.0 – 505.0)
Creatinine, mg/dL (range)	1.0 (0.7 – 1.3)	1.6 (0.4 – 6.6)
D-dimer, ng/mL (range)	1,194 (510.0 – 2,140)	1,481 (650.0 – 3,300)
LDH, U/L (range)	757.5 (340 – 1,307)	677.3 (526.0 – 846.0)
CRP, mg/dL (range)	13.6 (5.0 – 24.0)	16.8 (5.0 – 25.0)

pCO₂, partial pressure of carbon dioxide; pO₂, partial pressure of oxygen; sO₂, oxygen saturation; pO₂/FiO₂, fraction of inspired oxygen; ALT, alanine aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; CRP, C-reactive protein; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation; Dis, disease.